Elsevier

Clinical Therapeutics

Volume 26, Issue 1, January 2004, Pages 125-134
Clinical Therapeutics

Original research
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind, placebo-controlled, randomized clinical trial

https://doi.org/10.1016/S0149-2918(04)90013-6Get rights and content

Abstract

Background: Improving patients' health-related quality of life (HRQOL) could be a treatment goal for bipolar depression.

Objectives: The objectives of these secondary analyses of a previous report were to determine the benefits of olanzapine alone and olanzapine-fluoxetine combination (OFC) for improving HRQOL in patients with bipolar depression using both a generic and a depression-specific HRQOL instrument, and to examine the association between the 2 HRQOL instruments and the construct validity of the depression-specific HRQOL instrument.

Methods: This was a double-blind, placebo-controlled, 83-site, international, randomized trial. Adults with bipolar I disorder, most recent episode depressed (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), were randomly assigned to receive olanzapine (6–20 mg/d), OFC (6/25, 12/25, or 12/50 mg/d), or placebo for 8 weeks. HRQOL improvement was calculated as last-observation-carried-forward changes in dimension and component summary scores on Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and total score on the Quality of Life in Depression Scale (QLDS).

Results: Patients were assigned to receive olanzapine (n = 377), OFC (n = 86), or placebo (n = 370) for 8 weeks. Of 833 enrolled patients, 454 discontinued (olanzapine, 232/377 [61.5%]; OFC, 31/86 [36.0%]; and placebo, 191/370 [51.6%]). Compared with placebo, olanzapine-treated patients exhibited greater improvements on SF-36 mental component summary (MCS) score (P = 0.002) and 3 of 8 SF-36 dimension scores (mental health [P = 0.015], role-emotional [P = 0.046], and social functioning [P = 0.006]). OFC-treated patients exhibited greater improvements on MCS score (P < 0.001 vs both placebo and olanzapine), 5 SF-36 dimension scores (general health perception [P < 0.001 vs placebo; P = 0.007 vs olanzapinel, mental health [P < 0.001 vs both placebo and olanzapine], role-emotional [P < 0.001 vs placebo; P = 0.007 vs olanzapine], social functioning [P = 0.001 vs placebo; P = 0.032 vs olanzapine], and vitality [P = 0.002 vs placebo; P = 0.011 vs olanzapine]), and QLDS total score (P < 0.001 vs both placebo and olanzapine). Changes in SF-36 scores of mental health, social functioning, role-emotional, and vitality were highly correlated to changes in the QLDS total score (all p < −0.5).

Conclusions: Based on these analyses, patients with bipolar depression receiving olanzapine or OFC for 8 weeks had greater improvement in HRQOL than those receiving placebo. OFC treatment was associated with greater improvement in HRQOL than olanzapine alone. The correlation results support the construct validity of the QLDS.

References (51)

  • D.A. Regier et al.

    Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

    JAMA

    (1990)
  • D.W. Black et al.

    Is death from natural causes still exessive in psychiatric patients? A follow-up of 1593 patients with major affective disorder

    J Nerv Ment Dis

    (1987)
  • P. Lopez et al.

    Suicide attempts in bipolar patients

    J Clin Psychiatry

    (2001)
  • S.N. Ghaemi et al.

    Effectiveness and safety of long-term antidepressant treatment in bipolar disorder

    J Clin Psychiatry

    (2001)
  • T.A. Wehr et al.

    Rapid cycling in manic-depressives induced by tricyclic antidepressants

    Arch Gen Psychiatry

    (1979)
  • T.A. Wehr et al.

    Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients

    Am J Psychiatry

    (1988)
  • L.L. Altshuler et al.

    Antidepressant-induced mania and cycle accelaration: A controversy revisited

    Am J Psychiatry

    (1995)
  • G. Sachs et al.

    Divalproex versus placebo for the treatment of bipolar depression

  • J.R. Calabrese et al.

    A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group

    J Clin Psychiatry

    (1999)
  • J.R. Calabrese et al.

    A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group

    J Clin Psychiatry

    (2000)
  • R.M. Hirschfeld et al.

    Practice guideline for the treatment of patients with bipolar disorder (revision)

    Am J Psychiatry

    (2002)
  • M. Tohen et al.

    Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis

    Arch Gen Psychiatry

    (1990)
  • M. Tohen et al.

    Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group

    Am J Psychiatry

    (1999)
  • M. Tohen et al.

    Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group

    Arch Gen Psychiatry

    (2000)
    M. Tohen et al.

    Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group

    Arch Gen Psychiatry

    (2002)
  • M. Tohen et al.

    Olanzapine versus divalproex in the treatment of acute mania

    Am J Psychiatry

    (2002)
  • Cited by (55)

    • Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis

      2022, Psychiatry Research
      Citation Excerpt :

      Fig. 1) Nineteen studies from 22 reports were included.( Altshuler et al., 2017; Amsterdam and Shults, 2005; AstraZeneca, 2012; Brown et al., 2009, 2006; Tufts Medical Center and NIMH, 2017; Chen et al., 2017; Keck et al., 2005; Nemeroff et al., 2001; Niu and Mu, 2013; Nolen et al., 2007; Pang, 2015; Qiu, 2013; Sachs et al., 2007; Schaffer et al., 2006; Shelton and Stahl, 2004; Shen et al., 2011; Shi et al., 2004; Tohen et al., 2003; Tu, 2012; Yatham et al., 2016) One was an abstract reported as an E-poster of the 26th European Congress of Psychiatry(Kostyukova et al., 2018), two were unpublished results of studies in ClinialTrials.gov,(AstraZeneca, 2012; Tufts Medical Center and NIMH, 2017) and six were from Chinese databases.( Chen et al., 2017; Niu and Mu, 2013; Pang, 2015; Qiu, 2013; Shen et al., 2011; Tu, 2012) (Table 1)

    • Effects of venlafaxine versus lithium monotherapy on quality of life in bipolar II major depressive disorder: Findings from a double-blind randomized controlled trial

      2018, Psychiatry Research
      Citation Excerpt :

      In a review of the literature, Michalak et al. (2008) only identified 2 studies that tracked QoL outcomes in the treatment of bipolar depression. Using data from a sample of patients with bipolar I disorder, Shi et al. (2004) reported that the combination of olanzapine/fluoxetineproduced greater improvement in overall QoL ratings relative to placebo. Olanzapine monotherapy produced QoL changes that fell between those of the olanzapine/fluoxetine combination and placebo.

    • Receptor targets for antidepressant therapy in bipolar disorder: An overview

      2012, Journal of Affective Disorders
      Citation Excerpt :

      The same time the data are negative for paroxetine monotherapy (McElroy et al., 2010). Further analysis suggested that the OFC also improved many secondary indices (Shi et al., 2004) and could produce the beneficial effect already from day 7 (Dube et al., 2007). A small study (on 60 patients) without a placebo arm suggested that paroxetine and venlafaxine are equal, however this could be due to more drop outs in the venlafaxine group because of a higher switch rate, which balanced drop-outs in the paroxetine group due to lack of efficacy (Vieta et al., 2002).

    View all citing articles on Scopus
    View full text